Gynecologic Endoscopic Surgery of Female Motion Sickness Patients
Condition: Motion Sickness; Postoperative Nausea and Vomiting; Ibuprofen
MeSH terms: Vomiting; Postoperative Nausea and Vomiting; Motion Sickness
Study type: Interventional
Phase: Phase 4

Summary: 
      The goal of this clinical trial is to compare the analgesic effect of sufentanil and
      ibuprofen and the incidence of vomiting, and to choose better postoperative analgesic drugs
      for motion sickness patients.in describe participant population. The main questions it aims
      to answer are:

        -  Whether this anesthesia method can meet the analgesic needs of gynecological
           laparoscopic surgery.

        -  Whether this anesthesia method can reduce the incidence of nausea and vomiting in
           patients with motion sickness after gynecological laparoscopic surgery.

      Participants will use target-controlled infusion anesthesia combined with 0.8g ibuprofen
      injection.

      Researchers will compare with use of target-controlled infusion combined with sufentanil to
      see if the incidence of nausea and vomiting is higher.
    

Detailed description: 
      Abstract: Objective: To compare the analgesic effect of sufentanil and ibuprofen and the
      incidence of vomiting, and to choose better postoperative analgesic drugs for motion sickness
      patients. Methods: Sixty-eight female patients aged between 18 and 60 years with motion
      sickness were selected for gynecologic endoscopic surgery under general anesthesia.
      Sixty-eight female patients were randomly divided into two groups, Group B (ibuprofen group)
      and Group S (sufentanil group), using a random number table method. The initial plasma target
      concentration of propofol was set at 4ug/ml and adjusted using the titration method. Once the
      patient lost consciousness, the target concentration of remifentanil was set at 4ng/ml and
      rocuronium at 0.6mg/kg, followed by endotracheal intubation three minutes later. During the
      operation, the plasma target concentration of propofol was maintained at 5ug/ml and
      remifentanil at 4ng/ml, with adjustments made based on stress reaction levels. General
      anesthesia was sustained through continuous administration of rocuronium at doses of 5
      µg/kg/min. In Group B (ibuprofen group), intravenous administration of ibuprofen (0.8g) took
      place within half an hour before the end of surgery; in Group S (sufentanil group),
      intravenous injection of sufentanil (0.2ug/kg) occurred half an hour before completion of the
      operation, along with intravenous injection of dexamethasone (5mg) five minutes prior to
      anesthesia induction to prevent postoperative nausea and vomiting in both groups. The
      following data were collected: duration of operation, pneumoperitoneum time, extubation time,
      respiratory recovery time; Incidence of postoperative nausea and vomiting at different time
      intervals: Postanesthesia care unit residence period (T1), 0-3h after extubation (T2), 3-6h
      after extubation (T3), 6-12h after extubation (T4), 12-24h after extubation (T5); Visual
      analogue pain score : Postanesthesia care unit residence period (T1), 0-3h after extubation
      (T2), 3-6h after extubation (T3), 6-12h after extubation (T4), 12-24h after extubation (T5);
      Frequency of use of analgesics and antiemetic drugs; Incidence of adverse reactions within 24
      hours after surgery; Postoperative satisfaction.
    

Intervention name(s): Ibuprofen; sufentanil
Intervention type(s): Drug; Drug
Intervention description(s): 0.8g intravenous injection 30min before the end of the operation; 0.2ug/kg intravenous injection 30min before the end of the operation
Intervention MeSH terms: Ibuprofen; Sufentanil
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Prevention